Among the 11 genes in the signature, MMP12 (matrix metalloproteinase 12), PTGES3 (prostaglandin E synthase 3), and TERF2IP (telomeric repeat-binding factor 2-interacting protein 1) are involved in some clinical activities46, but their clinical association with CRC has been poorly reported, suggesting that these genes might be novel markers in CRC prognosis. Here, TERF2IP is linked to colorectal carcinoma.